Reflections on Using Non-Inferiority Randomised Placebo Controlled Trials in Assessing Cardiovascular Safety of New Agents for Treatment of Type 2 Diabetes

Evidence-Based Medicine - United Kingdom
doi 10.1136/ebmed-2017-110685
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ

Related search

Cardiovascular Safety of Non-Insulin Pharmacotherapy for Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2017English

Clinical Outcomes of an Integrated Primary–secondary Model of Care for Individuals With Complex Type 2 Diabetes: A Non-Inferiority Randomised Controlled Trial

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

A Meta-Analysis of Randomised Placebo-Controlled Treatment Trials for Depression and Anxiety in Parkinson’s Disease

PLoS ONE
Multidisciplinary
2013English

Cardiovascular Safety of Lumiracoxib: A Meta-Analysis of Randomised Controlled Trials in Patients With Osteoarthritis

European Journal of Clinical Pharmacology
MedicinePharmacology
2012English

Antibiotic Treatment for 6 Days Versus 12 Days in Patients With Severe Cellulitis: A Multicentre Randomised, Double-Blind, Placebo-Controlled, Non-Inferiority Trial

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Randomised Placebo-Controlled Trials of Surgery: Ethical Analysis and Guidelines

Journal of Medical Ethics
ArtsHumanitiesLegal AspectsHealth PolicyHealthEthicsIssues
2016English

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology
Pharmacology
2018English

Systematic Review and Meta-Analysis of Randomised, Other-Than-Placebo Controlled, Trials of Individualised Homeopathic Treatment

Homeopathy
Alternative MedicineComplementary
2018English

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Cureus
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy